Literature DB >> 14684377

SDF-1/CXCL12 regulates cAMP production and ion transport in intestinal epithelial cells via CXCR4.

Michael B Dwinell1, Hiroyuki Ogawa, Kim E Barrett, Martin F Kagnoff.   

Abstract

Human colonic epithelial cells express CXCR4, the sole cognate receptor for the chemokine stromal cell-derived factor (SDF)-1/CXC chemokine ligand (CXCL) 12. The aim of this study was to define the mechanism and functional consequences of signaling intestinal epithelial cells through the CXCR4 chemokine receptor. CXCR4, but not SDF-1/CXCL12, was constitutively expressed by T84, HT-29, HT-29/-18C1, and Caco-2 human colon epithelial cell lines. Studies using T84 cells showed that CXCR4 was G protein-coupled in intestinal epithelial cells. Moreover, stimulation of T84 cells with SDF-1/CXCL12 inhibited cAMP production in response to the adenylyl cyclase activator forskolin, and this inhibition was abrogated by either anti-CXCR4 antibody or receptor desensitization. Studies with pertussis toxin suggested that SDF-1/CXCL12 activated negative regulation of cAMP production through G(i)alpha subunits coupled to CXCR4. Consistent with the inhibition of forskolin-stimulated cAMP production, SDF-1/CXCL12 also inhibited forskolin-induced ion transport in voltage-clamped polarized T84 cells. Taken together, these data indicate that epithelial CXCR4 can transduce functional signals in human intestinal epithelial cells that modulate important cAMP-mediated cellular functions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684377     DOI: 10.1152/ajpgi.00112.2003

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

1.  The calmodulin-stimulated adenylate cyclase ADCY8 sets the sensitivity of zebrafish retinal axons to midline repellents and is required for normal midline crossing.

Authors:  Hong Xu; Sarah G Leinwand; Alison L Dell; Emma Fried-Cassorla; Jonathan A Raper
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  The role of polymorphisms of genes CXCL12/CXCR4 and MIF in the risk development IBD the Polish population.

Authors:  Jerzy Mrowicki; Karolina Przybylowska-Sygut; Lukasz Dziki; Andrzej Sygut; Jan Chojnacki; Adam Dziki; Ireneusz Majsterek
Journal:  Mol Biol Rep       Date:  2014-04-01       Impact factor: 2.316

3.  CXCR4 modulates contractility in adult cardiac myocytes.

Authors:  Robert T Pyo; Jinliang Sui; Ashwini Dhume; Julieta Palomeque; Burns C Blaxall; George Diaz; James Tunstead; Diomedes E Logothetis; Roger J Hajjar; Alison D Schecter
Journal:  J Mol Cell Cardiol       Date:  2006-09-28       Impact factor: 5.000

4.  Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia.

Authors:  Rebecca A Moyer; Michael K Wendt; Priscilla A Johanesen; Jerrold R Turner; Michael B Dwinell
Journal:  Lab Invest       Date:  2007-06-18       Impact factor: 5.662

5.  Calcium mobilization triggered by the chemokine CXCL12 regulates migration in wounded intestinal epithelial monolayers.

Authors:  Kimberle A Agle; Rebecca A Vongsa; Michael B Dwinell
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

6.  The chemokine CXCL12 and the HIV-1 envelope protein gp120 regulate spontaneous activity of Cajal-Retzius cells in opposite directions.

Authors:  Ivan Marchionni; Michael Beaumont; Gianmaria Maccaferri
Journal:  J Physiol       Date:  2012-04-02       Impact factor: 5.182

7.  Flagellin-independent regulation of chemokine host defense in Campylobacter jejuni-infected intestinal epithelium.

Authors:  Priscilla A Johanesen; Michael B Dwinell
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

8.  Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA.

Authors:  Noah P Zimmerman; Suresh N Kumar; Jerrold R Turner; Michael B Dwinell
Journal:  Inflamm Bowel Dis       Date:  2011-10-12       Impact factor: 5.325

9.  Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways.

Authors:  Luke J Drury; Joshua J Ziarek; Stéphanie Gravel; Christopher T Veldkamp; Tomonori Takekoshi; Samuel T Hwang; Nikolaus Heveker; Brian F Volkman; Michael B Dwinell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-11       Impact factor: 11.205

10.  CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Authors:  S Matsusaka; S Cao; D L Hanna; Y Sunakawa; M Ueno; N Mizunuma; W Zhang; D Yang; Y Ning; S Stintzing; A Sebio; S Stremitzer; S Yamauchi; A Parekh; S Okazaki; M D Berger; R El-Khoueiry; A Mendez; W Ichikawa; F Loupakis; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.